Gilead Sciences was recently ordered to pay $2.54 billion to Merck to resolve a long-running patent dispute concerning its blockbuster patent sellers Sovaldi (earning Gilead $19 billion) and Harvoni (earning Gilead $23 billion) for hepatitis C treatment.
The patent dispute originated with smaller companies that are now owned by two of the world’s largest drug makers.
Source: http://bit.ly/2hCrrhL
Summary
Article Name
Hepatitis C Patents Ruling means Gilead Ordered to Pay Merck $2.54 Billion
Description
Gilead Sciences was recently ordered to pay $2.54 billion to Merck to resolve a long-running patent dispute concerning its blockbuster patent sellers Sovaldi (earning Gilead $19 billion) and Harvoni (earning Gilead $23 billion) for hepatitis C treatment.
Author
Dawn Ellmore
Publisher Name
Dawn Ellmore Employment
Publisher Logo
